Tirzepatide (Mounjaro): How It Differs from Semaglutide and Labs

Tirzepatide — the active substance in Mounjaro and Zepbound — has become the most talked-about "weight-loss shot" of the past two years. It's often lumped together with semaglutide (Ozempic, Wegovy), but they are not the same: tirzepatide works differently and, in head-to-head trials, reduces weight more. Let's go through it calmly and without marketing: what this drug is, how it differs from semaglutide, what the large trials showed, what its risks are, and which labs it's sensible to monitor while taking it. There will be no doses, prices or "where to buy" tips here — this is a prescription medicine a doctor prescribes.

What Tirzepatide Is (Mounjaro, Zepbound)

Tirzepatide is an injectable drug given subcutaneously usually once a week, with a gradual dose increase. Under the Mounjaro brand it is used for type 2 diabetes, and under the Zepbound brand for obesity; the active substance is the same. Like semaglutide, it was originally created to control blood sugar in diabetes, and its strong weight-reducing effect became the second major indication.

How Tirzepatide Differs from Semaglutide

This is the key difference. Semaglutide (Ozempic, Wegovy) is an agonist of one receptor, GLP-1. Tirzepatide is a dual agonist: it activates two receptors at once, GIP and GLP-1. Both are incretin hormones the gut releases after eating; stimulating them together has a stronger effect on insulin release, appetite and fat metabolism. This "dual" action is thought to be why tirzepatide produces greater weight loss with a comparable tolerability profile.

In short: both tirzepatide and semaglutide work through the incretin system, but tirzepatide hits two targets while semaglutide hits one. More on semaglutide and the whole group — in Ozempic and semaglutide.

How It Works: GIP + GLP-1

The drug mimics two hormones the body normally produces in response to food. Through the GLP-1 and GIP receptors it enhances insulin release when sugar rises, suppresses excess glucagon, slows stomach emptying and acts on the brain's satiety centres. As a result appetite falls, a person feels full on less food, and blood sugar is better controlled. The same mechanisms also produce part of the side effects.

What the Trials Showed

Tirzepatide has been studied in large clinical trial programmes. In the SURPASS programme (type 2 diabetes) it was compared, among others, directly with semaglutide and showed greater reductions in sugar and weight. In the SURMOUNT programme (obesity without diabetes), 72 weeks of treatment led to average body-weight reductions of 16–22.5% depending on dose (SURMOUNT-1). Head-to-head against semaglutide in people with obesity (SURMOUNT-5, 2025), tirzepatide produced notably more weight and waist-circumference loss. That makes it one of the most effective drugs of this class today — but "more effective" does not mean "safe without monitoring."

Side Effects and Risks

The most common side effects are gastrointestinal: nausea, vomiting, constipation, diarrhoea. They are dose-related and usually lessen with gradual dose increase. Less often there are more serious risks: inflammation of the pancreas (pancreatitis), gallbladder problems, dehydration and strain on the kidneys from vomiting. The label carries a warning of risk for people with a personal or family history of medullary thyroid carcinoma and MEN 2 syndrome — for them the drug is contraindicated.

Who It's Prescribed For (and Who Cannot Take It)

It's usually prescribed for type 2 diabetes and obesity (or overweight with related diseases) when lifestyle change alone is not enough. Caution is needed with pancreatic and gallbladder disease and with severe kidney disease. The decision always rests with a doctor, who weighs indications, contraindications and concurrent medicines. It is not a "figure-correction" product on a whim.

Which Labs to Monitor While Taking It

Here our field is especially useful. A sensible basic check (in agreement with a doctor) — before starting and then over time, for example at 3 and 6 months: glucose and glycated haemoglobin (HbA1c) — effect and hypoglycaemia risk; insulin and an insulin-resistance estimate; a lipid panel — fat metabolism; liver enzymes (ALT) — the liver often improves with weight loss; kidney function; and TSH with caution about the thyroid. It's convenient to gather the key ones in one metabolic check-up. If you already have results, our service can read them in plain language.

Why a Doctor Matters and the Danger of "Grey" Sources

The main risk today is not the drug itself but buying "weight-loss shots" from unofficial, "grey" sources and self-dosing without supervision. This invites counterfeits, wrong dosing, no monitoring and missed contraindications. Tirzepatide is appropriate only on prescription and under a doctor's supervision, with baseline and follow-up labs. Weight loss "at any cost" without medical supervision is more dangerous than it seems.

This article is for informational purposes only, is not advertising or a prescription, and does not replace a doctor's consultation.